AbbVie in Oncology

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms.  Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology. 

Accord BioPharma is finding ways to reimagine therapies and help those who depend on their continued evolution with a pipeline of specialty products designed for patient needs

This attention to our patients, their abilities, and care goals is our approach, and our difference. It’s how we continue to challenge the status quo for patient and provider expectations in oncology, immunology, and neurology. The medicine may be where it starts, but in order to enhance the patients’ experience, we must deliver therapies that go beyond just the medicine, beyond biology.

Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Agamon Health is an AI-powered health technology company focused on improving oncology operations and patient care through intelligent workflow automation. The Agamon Health Coordinate platform automates chart preparation, cohort identification, and referral workflows, helping oncology providers translate complex clinical insights into timely, actionable care. By turning fragmented healthcare data into structured workflows, Agamon Health helps organizations close care gaps, improve operational efficiency, and support better outcomes across the oncology care journey. For additional information, visit  agamonhealth.com

AllyGPO and BioCareSD have partnered to transform specialty drug management for independent community practices with transparent and competitive pricing, smarter tools, and dedicated oncology expertise to strengthen practice performance. AllyGPO, a next-generation specialty GPO, enables members to operate more efficiently and improve practice vitality through advanced, AI-enabled technologies and proprietary practice intelligence tools that combine comprehensive GPO services, intelligent inventory management, and predictive practice analytics. BioCareSD, the original specialty drug distributor, brings nearly 50 years of expertise, exceptional customer service, and sustainable, eco-friendly cold-chain distribution. Learn more at www.AllyGPO.com and www.BioCareSD.com.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen is one of 30 companies comprising the Dow Jones Industrial Average^®, and part of the Nasdaq-100 Index^®. In 2025, Amgen was named to Fortune's list of the World’s Most Admired Companies.

For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, YouTube and Threads. 

Amneal Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and distributes generic, specialty, and biosimilar medicines.

In Practice™ , an Amplity property, is a best-in-class media platform built exclusively for oncologists and the multidisciplinary team in community settings. We deliver clinically relevant insights that support real-world cancer care where the majority of patients are treated—in our communities. Designed for depth and trust, In Practice curates expert perspectives, emerging data, and practice-ready resources in 1 centralized destination through multimedia delivery.

Annexus Health is the leading healthcare technology company that is revolutionizing the patient access journey by delivering innovative solutions, including tech-enabled services, that reduce financial and administrative burdens to improve access, speed, and adherence to critical care.

Welcome to Assertio

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Athena Oncology is a national network of independent, physician-led community oncology practices united by a shared commitment to preserving and strengthening high-quality cancer care close to home. Athena brings together practices across the country to collaborate, share expertise, and leverage collective resources while each member practice retains its full clinical autonomy and individual identity within its local community.

Through strategic collaboration, shared analytics, and pharmaceutical aggregation that responsibly leverages the collective scale of its member practices, Athena Oncology supports members in advancing clinical excellence, improving operational efficiency, and expanding patient access to innovative therapies. By aligning purchasing power and operational insights, Athena helps independent practices remain competitive while continuing to serve their local communities.

By connecting physician leaders, data experts, and partners across the oncology ecosystem, Athena Oncology creates a platform for independent practices to work together, exchange best practices, and sustain the long-term viability of community-based cancer care in the United States.

athenahealth strives to cure complexity and simplify the practice of healthcare. Our innovative technology includes electronic health records, revenue cycle management, and patient engagement solutions that help healthcare providers, administrators, and practices eliminate friction for patients while getting paid efficiently. We’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. Learn more at athenahealth.com 

Bayer is a global Life Sciences leader in cardiovascular disease, hematology, oncology, pulmonary hypertension and women’s health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives through its innovative therapies and its first-in-class educational and support programs. For more information, visit www.bayer.us.

At Boehringer Ingelheim, we are committed to improving patients' lives and continuously strive to embed the patient's perspective, voice, and insights into all that we do. We succeed by understanding patients’ needs and meeting those needs with innovative medicines and best-in-class engagements, programs, and services.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Conquer RCM complexity. Forever.

Remake your health insurance claims process with Candid Health – a transformative RCM automation platform, custom built for providers to end unnecessary human intervention. Increase net collections, reduce cost to collect, and accelerate cash flow with Candid.

Canopy is the leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting ~10% of oncology providers in the U.S. across 500+ sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.ai.

Cardinal Health meets oncology practices where they are, offering a choice of tailored solutions—from research programs and reliable distribution to innovative contracting, technology, and advanced services through our practice alliance. We empower community-based practices to navigate a dynamic healthcare environment by strengthening operations, improving efficiency, and expanding purchasing power. Together, we are building the future of high‑quality, compassionate, and cost‑effective cancer care. Learn more at cardinalhealth.com/oncology. 

Caris Life Sciences® is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Celcuity is a clinical-stage biotechnology company focused on developing a better way to address cellular abnormalities that drive tumor growth. Our teams of drug development scientists, biochemists, and molecular biologists are working to advance new targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway. This pathway plays a critical role as biological driver of a range of tumor types, including breast, prostate, lung, endometrial, colon, and ovary.

Our lead product candidate, gedatolisib, is a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, and/or mTORC1 alone or together. Gedatolisib thus offers hope to meaningfully extend the time that a patient’s tumors are not progressing.

Cencora, formerly AmerisourceBergen, empowers oncology physician practices and ensures their patients have access to the most innovative and cost-effective specialty care close to home. Through our ION Oncology Specialty GPO Network and Oncology Supply specialty distribution, along with our portfolio of integrated Specialty Solutions, we are a unified team of specialty practice partners, committed to building on our legacy of best-in-class service with meaningful innovation that supports our customers as they improve communities through patient-centric care.

We are now Cencora and are uniting our 46,000+ team members under one identity in pursuit of a shared purpose: our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #10 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.Cencora.com.

Resources for oncology practices

Colla Health is redefining mental health care in oncology. We partner with community cancer centers to embed a reimbursable, oncology-specific behavioral health program—powered by the Collaborative Care Model and purpose-built technology.

Integrated with leading oncology EMRs—including OncoEMR, G2 iKnowMed, and Epic—Colla Health fits seamlessly into existing workflows, expanding patient access to therapy and psychiatry while enabling sustainable revenue for partner practices.

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In oncology, cortisol may suppress apoptotic pathways, thereby reducing chemotherapy efficacy. Corcept is committed to investigating the role of selective GR antagonists (SGRAs) with clinical studies in ovarian, endometrial, cervical, pancreatic and prostate cancer. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com.

CuraScript SD provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.

Cureety is an oncology-specialized Digital Medical Device (CE-marked, FDA pathway underway) that enhances hybrid and outpatient cancer care. It provides structured remote monitoring, clinical triage, and workflow automation.

Cureety offers treatment-specific, patient-centric monitoring aligned with CTCAE grading and therapy-adapted triage, ensuring care teams prioritize patients effectively with clear guidance.

The platform integrates with existing oncology workflows and is configurable for institutional needs. Its digital modules automate crucial processes like prior authorization support, pre-infusion readiness checks, CAR-T and radioligand post-treatment monitoring, and coordinated communication, also simplifying reimbursement.

To date, more than 60,000 patients across France, Italy, Portugal, and Belgium have been supported through proactive monitoring via Cureety, in partnership with over 200 healthcare institutions, including hospital networks, academic medical centers, and community cancer programs.

Cureety’s mission is  to improve quality of life for patients undergoing complex cancer treatments and to restore time, strengthen capabilities, and support sustainable reimbursement for oncology care teams while improving quality and safety,

Current Health provides the infrastructure that unlocks lower-cost ambulatory, home, and community settings for high-risk patients, complex care, and advanced treatments.  

The Current Health AI-driven remote care platform combines high-touch biometric monitoring, clinical workflows, and critical care RNs who act as an extension of site teams.  

With our vast clinical data repository, we’re training the most advanced machine learning models to predict health events and safely scale treatment, recovery, and research wherever patients are.

At Daiichi Sankyo, we create essential medicine for longer, better lives. Every day, we strive to put our skills at the service of those most in need. By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication. We rely on reason, ingenuity, perseverance and empathy to make bold strides in oncology.

DeepScribe is the leading ambient AI platform for oncology, developed for the realities and complexities of cancer care. Today, DeepScribe is used by organizations representing about 90% of U.S. community oncology encounters, and captures nearly 4 million cancer visits annually.

Directly integrated into Ontada and Flatiron EHRs, DeepScribe produces accurate context-aware documentation, coding intelligence, and clinical insights within the flow of care. 

Clinicians have complete control over their notes’ structure, tone, and clinical nuance, contributing to DeepScribe’s industry-leading 85% adoption rate. DeepScribe also makes it easy for clinicians to collaborate seamlessly across care teams.

In 2025, KLAS Research awarded DeepScribe a 98.8 overall performance score, and three Top 5 rankings in its Emerging Solutions report.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

EmeritusDX is a leading cancer diagnostic laboratory committed to delivering precision, clarity, and confidence in every result. Our CAP-accredited and CLIA-certified laboratory provides comprehensive pathology and molecular testing designed to support accurate diagnoses and actionable clinical decisions.

By combining scientific expertise, advanced technology, and exceptional service, we help physicians navigate complex cases and improve patient outcomes.

Together, we save lives.

Exact Sciences is now Abbott, bringing our leading portfolio of cancer screening and diagnostics tests to the most diversified company in health. Our solutions help patients and healthcare providers make timely, informed decisions before, during and after a cancer diagnosis. Our growing product line includes well-established brands such as Cologuard and Oncotype DX, along with innovative solutions like the Cancerguard test for multi-cancer early detection and the Oncodetect test for molecular residual disease and recurrence monitoring. We continue to invest in a robust pipeline of advanced diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com.

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future.

People undergoing chemotherapy treatment often face significant challenges, and treatment-related hearing loss can add to that burden. Fennec Pharmaceuticals is fiercely devoted to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy.

The lifelong consequences of hearing loss can include barriers to communication, limitations in education and careers, strained relationships, and impacts on mental health. Hearing is essential to connecting with loved ones and engaging with the world around us. At Fennec Pharmaceuticals, we are dedicated to helping reduce the additional hardships faced by patients receiving cisplatin chemotherapy.

OncoEMR® is an industry-leading electronic health record for community oncology—supporting efficient, personalized, and evidence-based care across the patient journey. With intuitive workflows, customizable templates, and clinical content from trusted sources, OncoEMR® helps care teams work smarter, not harder. Over 4,700 providers across the Flatiron network of 1,000 community-based cancer care locations use OncoEMR® for patient care and practice operations.

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

Forte Bio-Pharma (also known as Forte BioPharma) is a specialty pharmaceutical compnay dedicated to advancing pain management through innovative in-licensing, development, and commercialization of novel medications. Founded in 2018 by a team with over 90 years of combined pharmaceutical expertise, we are committed to delivering unique dosage options and improved therapies for unmet medical needs. Our mission is to bring better health and a brighter future to patients by providing healthcare providers with differentiated solutions in pain management.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Genmab is recognized for its expertise in antibody science. The company continues to advance its late-stage pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Visit Genmab.com, LinkedIn and X.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achived breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.  The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, Covid-19, and Cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gosta Labs is a healthtech company redefining healthcare with artificial intelligence. The company is developing an AI operating system for complex medical specialties, like oncology, enabling more efficient, precise, and personalized care across the entire patient journey.

Founded in 2023 by the former founders of Kaiku Health (acquired by Elekta in 2020), Gosta Labs partners with leading healthcare providers in Finland, Switzerland, the Baltics, and Australia. The company is backed by investors including Voima Ventures, COR Group, the Aho family, Reaktor and a group of notable angel investors. For more information, visit www.gostalabs.com

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

HealthTree is a free platform that helps blood cancer patients become more informed, organized, and connected, so they can better navigate treatment and partner more effectively with their care team. Through HealthTree, patients can track their disease data, learn about treatment options and clinical trials, access trusted education from experts, and connect with a community that understands their diagnosis. By supporting patients outside the clinic, HealthTree helps reduce confusion and empower patients to take a more active role in their care.

House Rx is a healthcare technology and services company focused on making specialty medication more accessible and affordable for those suffering from chronic illnesses like cancer and autoimmune disorders. House Rx provides clinics with specialized technology and support from pharmacists and care coordinators to dispense medication directly to their patients, known as medically integrated dispensing (MID). By helping physicians and pharmacists collaborate on patient care, House Rx is able to improve patient outcomes, lower the cost of care, and create a better experience for patients and their caregivers.  To learn more about House Rx, visit www.houserx.com.

ImagineSoftware™ is the leading provider of revenue cycle management technology, including medical billing automation software and Artificial Intelligence-driven platforms. Offering powerful technology solutions for medical billing offices, physician practices, and hospitals for over 25 years, ImagineSoftware™ currently serves more than 75,000 physicians across 47+ specialties. ImagineSoftware™ solutions improve financial efficiency, build provider reputation, and ultimately enhance the patient experience. For more information, visit imagineteam.com and follow us on Twitter @ImagineTeam or connect with us on LinkedIn “ImagineSoftware (Technology Partners, LLC)”

Incyte is a Biopharmaceutical Company on a Mission to Solve On. Solve On. speaks to our relentless pursuit to find answers for patients by following the science. It inspires us to bring advances for those with unmet medical needs, regardless of the disease or size of the patient population. And, it reminds us that patients are waiting. That spirit, energy and excitement is felt across the company each day.

We are a value-based, precision medicine company. We are changing the way cancer care is delivered, research pursued, advancements embraced, and costs managed by enabling providers, health systems, payers, and life sciences companies to apply clinical and claims data, deep expertise, and sophisticated technologies to the decisions that matter.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care, At Ipsen, we develop and commercialize medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Our focus in oncology is on some of the most difficult-to-treat cancers. We have a growing portfolio of therapies for solid tumors and in hematology aimed at improving the lives of people living with pancreatic cancer, gastrointestinal and pancreatic neuroendocrine tumors, and carcinoid syndrome. Every day, our more than 5,000 employees worldwide, including nearly 800 in North America, work diligently to improve lives around the world. For more information, please visit

www.ipsen.com/us

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

Johnson & Johnson is a global healthcare leader, committed to solving the toughest health challenges and transforming lives through research, development, manufacture and distribution of medicines and medical technologies. The company’s Innovative Medicine business advances breakthrough science and develops transformational treatments in areas like oncology, immunology, neuroscience, and cardiopulmonary. In MedTech, the company is focused on developing and delivering cardiovascular, surgery, and vision solutions. Visit jnj.com to learn more.

Knowtex is a 2022 women-founded company led by Stanford AI scientists that is headquartered in San Francisco, building ambient clinical intelligence to transform how clinicians capture and use medical information. Designed to be EHR-agnostic, specialty-specific, and deeply integrated into workflows, Knowtex enables providers to generate complete, accurate notes, codes, and orders in real time. By combining clinical-grade AI with enterprise-grade security and speed, Knowtex helps health systems and providers reclaim time, reduce burnout, and deliver comprehensive patient care.  

AI for intelligent patient communication and navigation across the care journey.

Using context-aware Voice and SMS agents, Kouper orchestrates inbound and outbound interactions across access, care navigation, and follow-up — helping organizations close care gaps, improve patient access, and reduce operational burden. Kouper integrates directly into existing clinical and operational workflows, enabling healthcare organizations to reach the right patient, at the right moment, with the right action — without adding staff or complexity.

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. 

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world.

The Labcorp oncology portfolio supports cancer care from screening and risk assessment, through diagnosis and prognosis, therapy selection and monitoring and surveillance. Through a full spectrum of clinical and oncology tests, including liquid biopsy, tissue-based comprehensive genomic profiling, and companion diagnostics, Labcorp partners with oncologists, health systems and biopharma companies to drive precision medicine, improving outcomes and expanding access for patients globally.

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

LeanTaaS is the leading provider of AI-powered and cloud-based capacity management, staffing, and patient flow software and services for healthcare organizations. Our iQueue products for operating rooms, surgical clinics, infusion centers, and inpatient units use Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively in response to avoid operational bottlenecks before they happen. 

The result? Expensive assets are utilized better, hospital ROI improves, patient access increases, and clinicians work at the top of their license with reduced administrative burden.  

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.

Built by physicians, revenue cycle leaders, and software engineers, Luma MDX integrates with EHR systems to turn clinical conversations into structured context that accelerates charting, streamlines prior authorization, and powers real-time clinical and financial analytics.

Powerful AI-driven solutions for clinical workflow automation, charting, and revenue cycle performance.

Luma MDX helps oncology and multi-specialty teams reduce administrative burden and improve financial outcomes with an ambient AI layer — combining virtual assistants, workflow automation, and actionable analytics.

Marvix AI is an ambient AI assistant for Oncology. It listens securely to patient visits and combines them with the patient’s historical record from the EHR to create structured clinical notes in your writing style for the problems that you see most. It captures detailed patient history, oncologic symptoms, diagnosis, performance status (ECOG and Karnofsky scores), and comprehensive treatment details.

Marvix is built for long consults & complex oncology documentation, supports pre-charting and combining MA and physician workflows, generates after-visit summaries, referral letters, and DDx reports, and generates ICD-10 CM and E/M codes along with MDM rationale, and integrates 2-way with 12 leading EHRs.

Oncology-specific Notes:

Captures detailed history, Oncological symptoms, diagnosis, ECOG, Karnofsky Scores and treatment details. Understands context-specific language and structures complex exam findings and assessments automatically.

Custom Templates:

Creates custom templates for each provider for different medical and visit type scenarios such as Palliative Care Management, Surgeries 

Pre-charting & Post-visit Dictations:

Supports multiple recordings for pre-charting as well as post visit dictations for the same visit and creates a coherent logical narrative.

Team Workflows:

Enables collaboration across teams - precharting by MAs, history by Nurses and Assessments by MDs on a single encounter

Multilingual:

Supports 99 languages, 1000s of accents, translators and multiple speakers in the same Consult.

AI Coder:

Generates ICD-10-CM and E/M codes with MDM rationale.

AI Summarizer:

Auto extracts and summarizes prior notes, labs, imaging, discharge summaries and other medical documents to inform the current note

After Visit Summaries:

Generates After Visit Summaries, Pre-op consent, MRI / X-ray, imaging or biopsy dictations & Referral letters.

AI Dictation:

Inserts verbatim dictation with high medical accuracy anywhere in your notes anytime.

Semantic Macros:

Adds dynamic content (eg. Physical Exams for breast or prostate cancer) or preset text (e.g. procedure descriptions, side effects of drugs) to notes by inferring context from the consult.

Technical Inference:

Captures Assessments and Labs, Imaging, Pathology findings in medical terms without layman terms used in the conversation with the patient 

Seamless EHR Integration:

2-way integration with multiple EHRs, real-time sync of notes and appointments, and carrying forward of patient histories.

The US Oncology Network and McKesson power a connected ecosystem in community oncology and specialty care. Together, we enable thousands of independent providers with integrated solutions that streamline care delivery, expand access to advanced therapies, and bring high‑quality cancer and specialty care closer to home. 

Powering Data-Driven Decision Making

Our mission is to advance healthcare quality through actionable, data-centered intelligence, bridging gaps and empowering better outcomes for all stakeholders in the healthcare ecosystem.

Together, we can turn data into breakthroughs.

Medscape is the leading source of clinical news, health information, and point-of-care tools for health care professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free C.M.E. and C.E. courses and other educational programs for physicians, nurses, and other health care professionals. Medscape is a subsidiary of WebMD Health Corp.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Natera^™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.

Navigating Care has been a trusted leader in digital oncology solutions since 2008, helping community oncology practices transform care delivery. We provide a comprehensive, intelligent digital health platform designed to optimize patient engagement, streamline clinical workflows, and enhance care outcomes to oncology practices and their patients nationwide. Our advanced, mobile-friendly portal enables patients to seamlessly access test results, securely message their care team, and receive tailored education personalized to their treatment journey. With our proactive symptom and medication monitoring system (Health Tracker), Navigating Care leverages real-time data to identify and prioritize patients requiring immediate attention, and empowers care teams to intervene early, improving outcomes while reducing hospitalizations. By automating routine workflows and centralizing communication, our platform ensures triage, nursing, and operations teams can efficiently manage urgent cases and focus on high-value patient care. Navigating Care integrates seamlessly with leading EMR systems, enabling oncology practices to enhance care delivery without disrupting existing processes. Our intelligent platform reduces administrative burden, improves reimbursement opportunities, and empowers practices to deliver continuous, proactive care—improving outcomes for both patients and practices.

Navista is an oncology practice alliance that provides advanced services, technology and financial support to help community practices remain independent and fuel their growth. Our mission is to empower community practices to deliver personalized, patient-centered cancer care, close to home, while acting with the speed and agility cancer care deserves. Navista includes more than 50 practice sites delivering multidisciplinary oncology care nationwide. As a Cardinal Health company, we have the resources to invest in our alliance member practices for long-term success and help preserve each practice’s legacy of exceptional care. Together with our members, Navista unlocks the power of community oncology to help practices stay independent—for the good of their patients, practice and community. To learn more, visit Navista.com or follow us on LinkedIn. 

NeoGenomics is a premier cancer diagnostics company, specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP accredited and CLIA certified laboratories for full-service sample processing and analysis services throughout the US; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

Nuvation Bio is a late-stage, global pharmaceutical company tackling some of the greatest unmet needs in oncology. Our vision is to significantly change the treatment of cancer by developing novel and differentiated medicines that provide truly meaningful improvement in survival and quality of life for people around the world. 

At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.

OncoLogic is the world’s first and most advanced Oncology Process Orchestration Platform™, purpose-built for community oncology and your EHR. The platform connects real-time oncology research, advanced clinical reasoning, and operational workflow automation into a single intelligence layer that helps practices reduce administrative burden, keep pace with rapidly evolving science, and move patients to therapy faster.

OneOncology was founded by community physicians, for community physicians, with the mission of improving the lives of everyone living with cancer and other diseases. Our goal is to enable community medical practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports our platform of community medical practices through group purchasing, operational optimization, practice growth, and clinical innovation. Our partner practices comprise approximately 2,300+ providers who care for approximately 1.5 million patients in 20 states. To learn more, visit oneoncology.com. 

Organon is a global healthcare company with a vision to create a better and healthier every day. We believe in the potential of biosimilars, and we are dedicated to delivering biosimilars to the health care system today, tomorrow, and beyond. Through collaboration at every level, we get closer to unlocking the value that biosimilars can create.

PatientPoint is the leading digital health company that connects patients and healthcare providers with the right information in the moments care decisions are made. Our solutions are proven to improve health outcomes, patient eduction and operational efficiency. Across the nation's largest network of connected digital devices in 30,000 physicial offices, PatientPoint solutions empower better health for millions of patient visits each year.

Oncology practices use PatientPoint solutions to educate and inspire patients, caregivers and their staff-enhancing the patient experience while improving health outcomes. Learn more at Patient Engagement Solutions for Oncology | PatientPoint

For over 25 years, Paxman had lead the way for chemotherapy side-effect management solutions, specifically for chemotherapy-induced alopecia and now peripheral neuropathy. The Paxman Scalp Cooling System is clinically proven to reduce hair loss and promote faster regrowth, offering patients a degree of control over their diagnosis. This treatment is now reimbursable via Category I CPT® codes.

A cryocompression device to help prevent chemotherapy-induced nerve damage is currently undergoing regulatory approvals, with commercialization planned for later this year.

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. 

We are a family-owned company innovating in iron metabolism, blood disorders, and cell cycle biology. With 700+ employees globally, we prioritize quality, collaboration, and  patient care to drive life-changing treatments.

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

PharmaEssentia, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.

Activated patients.
Improved outcomes.

Phreesia is the trusted leader in patient activation, powering 170M+ patient visits annually—more than 1 in 7 visits nationwide. We help community oncology practices streamline intake, access, payments and clinical workflows with automated, patient-driven digital tools that reduce administrative burden and enhance the patient experience. By freeing staff from manual processes, Phreesia enables your team to focus on what matters most: delivering high-quality, patient-centered cancer care.

Prism TPO is a technology-enabled transparency platform serving independent specialty practices. Founded in 2024 by a team of industry veterans, the company was created to bring clarity to the increasingly complex economics of oncology drug purchasing, where treatment costs now exceed a median of $196,000 per patient annually. The platform translates fragmented manufacturer, distributor, and reimbursement data into structured, actionable insight, enabling independent practices to make confident purchasing decisions with greater predictability. By leveraging collective scale, disciplined contracting, and real-time analytics, Prism delivers fairness, trust, and durable economics in a historically opaque market.

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Qure4u’s all-in-one AI platform automates every step of the patient journey—from scheduling and check-in to payments and follow-up—turning engagement into measurable revenue. With 60–80% self-scheduling adoption, 90–100% pre-check-in rates, and 99% time-of-service collections, Qure4u helps practices fill more appointments, collect payments faster, and convert everyday workflows into growth. It’s AI built to drive revenue—streamlining operations while keeping schedules full and cash flowing.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

At Reimagine Care, we start with a simple truth: people facing cancer need support that meets them where they are, when they need it most. They deserve to thrive as whole human beings, surrounded by the support they need. 

We partner with oncology providers to make this possible through an AI-enabled virtual care platform that extends compassionate, expert care beyond clinic walls. Our technology doesn’t replace the human touch; it amplifies it. By providing 24/7 access to oncology-trained clinicians and resolving 95% of patient needs virtually, we reduce avoidable emergency visits and free physicians from the constant cycle of after-hours calls and administrative burden. 

The result is transformative for everyone: patients receive proactive, and convenient access to the care they need, while oncologists reclaim the capacity and joy that drew them to medicine in the first place. 

Our vision: harness the power of AI to make cancer care profoundly more human and accessible for everyone it touches across the patient journey. We’re building the trusted standard for how patients and providers navigate cancer together. 

Resilience Care is a digital oncology company dedicated to eliminating the “blind spot” between clinic visits through a model of continuous cancer care. Currently utilized by over 200 leading oncology centers internationally, the company provides a clinical-grade system for remote symptom monitoring and management that allows care teams to detect treatment toxicities early and intervene proactively. The offering is designed to maximize nurse efficiency by streamlining workflows and prioritizing high-risk cases, while empowering patients with the personalized tools and support they need to stay on treatment safely. By transforming daily patient data into structured clinical insights, Resilience Care helps healthcare providers improve clinical outcomes and capture new revenue streams through proactive, data-driven care.

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancers.

RISA is building an AI platform purpose-built for oncology, starting with the workflow that blocks patient access most: Prior Authorization.

RISA solves both Part B and Part D prior auth through a single platform, automating eligibility verification, medical necessity documentation, and payer submission across 1,400+ oncology drugs. Live today with New York Cancer & Blood Specialists, Astera Cancer Care, OneOncology, and 10+ practices, processing 50,000+ transactions monthly — RISA has delivered a 97% first-submission success rate, 99.5% date-of-service authorization, and 70% of FTE time reclaimed by admin & clinical staff, with time to treatment cut by 50%. The network is on track to reach 20+ practices by end of Q2.

The company is backed by Cencora, Optum Ventures, and Oncology Ventures.

Prior auth is the first workflow. Building on the same foundation, select practices have already begun expanding into other RCM workflows, including claims management and denial resolution, and upstream into clinical trial patient identification and evidence-based care adherence building toward a full AI operating system for oncology teams.

RxToolKit is a software solution for biologic and oncology medications, designed to reduce errors and improve patient safety. RxWorkFlow provides medication guides with drug information. RxELearning offers drug-specific training for clinical teams, enhancing competencies.

RxVantage is transforming the way physicians and their practice teams make healthcare connections that elevate the practice of medicine. The only all-in-one provider-preferred engagement platform of its kind, RxVantage intelligently connects healthcare providers with resources, including the precise life sciences field experts, when they need them and in a manner that fits seamlessly into their workflow.

For more information, visit www.rxvantage.com

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of 
science to help improve people’s lives. We aspire to drive the evolution of cancer treatments, transform patient care, and impact the lives of people living with cancer. Our purpose motivates us to push 
science to the next level. And we never settle. 

If using BRANDED booth (appropriate use in PROXIMITY to products and not JUXTAPOSED; clear 
delineation between marketed product and corporate claim. To be reviewed by Regulatory before use 
when feasible): 

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of 
science to improve people’s lives. We are dedicated to developing novel treatment options, expanding 
access to therapies, providing patient support resources and working with patient organizations to 
understand both patient and caregiver needs.

SCIO Management Solutions

Most infusion practices are not losing money because of reimbursement rates. They are losing money because of revenue cycle inefficiencies they cannot see.

In oncology and other infusion driven specialties, the difference between strong financial performance and constant margin pressure often comes down to how well a practice manages payer policy, drug reimbursement, coding accuracy, and authorization workflows. Small breakdowns in these areas can quietly drain millions in drug revenue.

SCIO Management Solutions was built specifically to solve that problem.

We specialize in the complex revenue cycle surrounding high cost drugs and biologics. Our team works with oncology and infusion practices to identify hidden revenue leakage, strengthen reimbursement strategy, and improve operational performance across the revenue cycle.

Unlike traditional outsourcing models, SCIO is built around flexibility. Many practices do not need or want to outsource their entire revenue cycle. Our hybrid model allows organizations to retain the functions they perform well while leveraging SCIO for the areas that require specialized expertise such as prior authorizations, infusion coding, AR recovery, denial management, revenue cycle audits, and strategic consulting.

The result is a smarter revenue cycle, stronger net collections, and a financial infrastructure designed to support the long term sustainability of community based specialty care.

Servier Pharmaceuticals is the U.S. affiliate of the Servier Group, focused on delivering transformative oncology and neurology medicines for patients underserved by current therapies. Since launching in Boston in 2018, Servier has become a leader in cancer care, advancing a portfolio of precision therapeutics. Governed by a nonprofit foundation, its private structure supports long-term innovation. Servier actively pursues partnerships across all stages of R&D to accelerate treatment delivery. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sobi is a global biopharma company unlocking the potential of breakthrough therapies, transforming everyday life for people living with rare diseases.

Stemline Therapeutics, Inc. ("Stemline") a wholly-owned subsidiary of the Menarini Group, is a
commercial-stage biopharmaceutical company focused on the development and commercialization of
novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers
are committed to providing transformational oncology treatments to those who need them, with the
ultimate goal of improving the lives of those impacted by cancer.

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor and a monoclonal antibody that blocks the CSF-1 receptor. For more information, visit www.syndax.com or follow the Company on X and LinkedIn.

The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.

TailorMed is a comprehensive, end-to-end platform designed to eliminate barriers along the entire medication journey, from affordability to access and adherence. TailorMed’s innovations in healthcare are transforming how stakeholders—patients, providers, pharmacies, life sciences, and payers—work together to ensure that every patient, across all medical conditions, can receive the treatment they need without delay. TailorMed's enterprise solution manages the full lifecycle of patient support programs, reducing the cost of care and driving better outcomes. Thanks to its partnerships with life sciences, TailorMed creates unparalleled automation through direct integration with manufacturer assistance programs. With the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 1,400 pharmacies, TailorMed powers organizations to create a seamless patient experience. Learn more at tailormed.co.

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere.  We ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.  Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.

Tennr is a referral automation platform that helps healthcare operators capture more referrals, cut denials, and deliver faster care without scaling their teams, while providing visibility into patients’ care statuses. Tennr uses a combination of automation workflows and proprietary specialized language models (RaeLM™) to automate document triaging, intake, insurance verification, and outreach for missing information, reducing the likelihood of patients being lost in the referral handoff. Tennr reduces first-pass denials caused by error-prone, manual processing and enables providers to focus on patient conversion, referral retention, and efficient growth. 

The secret behind Tennr is the combination of an enterprise orchestration engine and a series of specialized language models (RaeLM™) trained on the nuances of processing medical documentation against strict payer criteria. Unlike generic large language models, RaeLM is optimized to understand the nuanced data in medical determinations across years of records. It evaluates documents against complex payer criteria to flag potential denials.

Tennr’s models are benchmarked as the most accurate in healthcare. There’s no black-box when it comes to Tennr’s automations; you can see exactly how accurately the model is performing at any time. Other solutions also rely on repeat “one-size-fits-all” automations that are limited and can’t drive value in most business scenarios.

Thermo Fisher Scientific delivers end-to-end next-generation sequencing (NGS) solutions that advance precision medicine, from sample preparation and sequencing platforms to bioinformatics and clinical reporting. Our Oncomine™ solutions for solid tumors enable comprehensive genomic profiling from challenging FFPE and low-input samples, detecting key biomarkers—including SNVs, indels, CNVs, and gene fusions—in a single streamlined workflow, with biomarker results available in as little as 24 hours. Designed to support timely therapy selection and clinical decision-making, Oncomine assays combine robust performance, simplified workflows, and curated oncology content to help labs confidently deliver actionable results. 

Thyme Care is the leading value-based care enabler, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Thyme Care's approach combines a technology-enabled Care Team and seamless integration with providers, creating a hybrid collaborative care model that guides and supports the entire patient journey. Thyme Care empowers oncologists nationwide through purpose-built tech, advanced data analytics, and virtual patient engagement, driving better care and outcomes in value-based arrangements. To learn more about how Thyme Care is enabling the shift to value-based care in oncology, visit https://www.thymecare.com/.

Automate patient phone calls across scheduling, refills, intake, and after-hours workflows. All while improving access, reducing wait times, and lowering operational costs.

The Leader In Practice management software

Increase Revenue And Decrease Cost to Collect

The modern practice management platform your practice has been waiting for. The only medical billing & RCM software solution built exclusively for specialty healthcare.

Powered by Artificial Intelligence.
Built for Human Intelligence.

We’re proud to be one of the most advanced and modern medical software companies in the United States. Watch the powerful benefits our practice management software can bring to your practice.

VieCure, a cancer care innovation company, offers a proprietary digital ecosystem, Halo Intelligence™, powered by artificial intelligence (AI) informatics, a clinical inference engine, and a purpose-built oncology electronic medical record (EMR). Halo Intelligence™ provides real-time clinical decision support by integrating patient data with evidence-based knowledge and digital workflows at the point of care, enabling oncologists to design personalized, comprehensive care plans across diagnosis, treatment, and follow-up. VieCure partners with cancer centers throughout the United States and maintains strategic alliances with Life Science organizations focused on advancing cancer care. 

Willow Risk Advisors is an insurance broker specializing
in professional liability (malpractice) insurance and related
coverage within the healthcare industry. Our primary clients
include physicians, ancillary healthcare providers, outpatient
surgery centers, miscellaneous healthcare facilities, and
hospitals. We are licensed throughout the United States, and our reach extends to European markets.

Zydus Pharmaceuticals (USA) Inc. is part of Zydus Lifesciences Limited, a global life sciences company committed to improving access to high-quality medicines. Zydus operates in more than 50 countries and supports patients worldwide through a broad, growing portfolio of treatments and a global network of over 30 manufacturing facilities.

In the United States, Zydus is expanding its oncology presence with Beizray^TM (docetaxel injection), providing an exciting treatment option for patients receiving cancer care.